Nephron Launches New Syringe Presentation
/PRNewswire/ -- Continuing to build on the momentum that comes with explosive growth, Nephron Pharmaceuticals Corporation today announced the launch of a brand...
Stay updated with breaking news from Outsourcing Facility. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Continuing to build on the momentum that comes with explosive growth, Nephron Pharmaceuticals Corporation today announced the launch of a brand...
Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth Kennedy: Company Excited to Expand Generic Portfolio to Include Non-Respiratory Products News provided by Share this article WEST COLUMBIA, S.C., Dec. 22, 2020 /PRNewswire/ -- Nephron Pharmaceuticals Corporation is celebrating another milestone. The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials. The vials are made of polypropylene plastic with a "luer lock" ...
Posted on 511 Wedgewood Pharmacy has signed a definitive purchase agreement with Partners Group, on behalf of its clients, which will replace New Harbor Capital as its majority shareholder after the transaction closes in 2021. Terms of the transaction were not disclosed. Marcy A. Bliss, CEO of Wedgewood Pharmacy, said: “While we have achieved excellent results under New Harbor’s ownership, we are very excited to collaborate with Partners Group going forward. They are deeply experienced professionals who have extensive healthcar...